help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2004-2552
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matsumoto, T.
Right arrow Articles by Nakamura, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsumoto, T.
Right arrow Articles by Nakamura, T.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*1,25-DIHYDROXYCHOLECALCIFEROL
*CALCIUM COMPOUNDS
*CALCIUM, ELEMENTAL
Medline Plus Health Information
*Osteoporosis
Related Collections
Right arrow Calcium and Bone Metabolism
The Journal of Clinical Endocrinology & Metabolism Vol. 90, No. 9 5031-5036
Copyright © 2005 by The Endocrine Society

A New Active Vitamin D, ED-71, Increases Bone Mass in Osteoporotic Patients under Vitamin D Supplementation: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Toshio Matsumoto, Takami Miki, Hiroshi Hagino, Toshitsugu Sugimoto, Sumiaki Okamoto, Takako Hirota, Yusuke Tanigawara, Yasufumi Hayashi, Masao Fukunaga, Masataka Shiraki and Toshitaka Nakamura

Department of Medicine and Bioregulatory Sciences (T.Ma.), University of Tokushima Graduate School of Health Biosciences, Tokushima 770-8503, Japan; Osaka City University (T.Mi.), Osaka 545-0051, Japan; Tottori University (H.H.), Tottori 683-0826, Japan; Kobe University (T.S.), Kobe 650-0017, Japan; Sanyo Osteoporosis Research Foundation (S.O.) Oita 870-0924, Japan; Tsuji Academy of Nutrition (T.H.), Osaka 530-0021, Japan; Keio University Hospital (Y.T.), Tokyo 160-8582, Japan; Tokyo Metropolitan Geriatric Hospital (Y.H.), Tokyo 173-0015, Japan; Kawasaki Medical School (M.F.), Kurashiki 701-0192, Japan; Research Institute and Practice for Involutional Diseases (M.S.), Nagano 399-8101, Japan; and University of Occupational and Environmental Health (T.N.), Fukuoka 807-8582, Japan

Address all correspondence and requests for reprints to: Toshio Matsumoto, M.D., Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan. E-mail: toshimat{at}clin.med.tokushima-u.ac.jp.

Context: ED-71 has been shown to increase lumbar bone mineral density (BMD) in osteoporotic subjects. However, vitamin D insufficiency might have influenced the effect of ED-71 on BMD.

Objective: Our objective was to examine whether ED-71 can increase BMD in osteoporotic patients under vitamin D supplementation.

Design, Setting, and Patients: We conducted a randomized, double-blind, placebo-controlled clinical trial of 219 osteoporotic patients (49–87 yr of age).

Interventions: Subjects were randomly assigned to receive placebo or 0.5, 0.75, or 1.0 µg/d ED-71 for 12 months. All the subjects received 200 or 400 IU/d vitamin D3.

Main outcome measures: We assessed changes in lumbar and hip BMD and bone turnover markers from baseline.

Results: Lumbar BMD increased with ED-71 treatment for 12 months (2.2, 2.6, and 3.1% from baseline and 2.9, 3.4, and 3.8% vs. placebo group in subjects receiving 0.5, 0.75, and 1.0 µg ED-71, respectively). Total hip BMD also increased with 0.75 and 1.0 µg ED-71 (–0.8, 0.6, and 0.9% from baseline and 0.1, 1.5, and 1.8% vs. placebo group in the 0.5, 0.75, and 1.0 µg ED-71 groups, respectively). Bone formation and resorption markers were suppressed by approximately 20% after 12 months of 0.75 and 1.0 µg ED-71 treatment. Transient hypercalcemia over 2.6 mmol/liter occurred in 7, 5, and 23% of subjects in the 0.5, 0.75, and 1.0 µg ED-71 groups, respectively, but none of them developed sustained hypercalcemia.

Conclusions: These results demonstrate that ED-71 treatment at around 0.75 µg/d can effectively and safely increase lumbar and hip BMD in osteoporotic patients with vitamin D supplementation.




This article has been cited by other articles:


Home page
Anticancer ResHome page
N. KUBODERA and S. HATAKEYAMA
Synthesis of All Possible A-ring Diastereomers at the 1- and 3-Positions of 1{alpha},25-Dihydroxy-2{beta}-(3-hydroxypropoxy)vitamin D3 (ED-71) Using C2-Symmetrical Epoxide as a Common Starting Material
Anticancer Res, September 1, 2009; 29(9): 3571 - 3578.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
H. A. Bischoff-Ferrari, W. C. Willett, J. B. Wong, A. E. Stuck, H. B. Staehelin, E. J. Orav, A. Thoma, D. P. Kiel, and J. Henschkowski
Prevention of Nonvertebral Fractures With Oral Vitamin D and Dose Dependency: A Meta-analysis of Randomized Controlled Trials
Arch Intern Med, March 23, 2009; 169(6): 551 - 561.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society